---
title: "Lakewood-Amedex Soars 17% in Regular Trading on Positive Nu-3 Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300313616.md"
description: "LABT surges 17% on positive lab results for Nu-3 drug candidate targeting diabetic foot ulcers."
datetime: "2026-09-28T13:34:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300313616.md)
  - [en](https://longbridge.com/en/news/300313616.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300313616.md)
generator: "portal-rs"
---

# Lakewood-Amedex Soars 17% in Regular Trading on Positive Nu-3 Data

Lakewood-Amedex Biotherapeutics(LABT.US) 盘中涨**17.37%**，现报**1.96 美元**。

公司宣布其候选药物 Nu-3 针对感染性糖尿病足溃疡分离株的实验室数据呈积极结果，显示出对耐药病原体的广泛活性。Nu-3 目前正在进行针对轻度感染糖尿病足溃疡的 2a 期局部试验，顶线结果预计于 2027 年第一季度公布。管理层认为该数据支持在这一高风险领域的持续开发。

### Related Stocks

- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)

## Related News & Research

- [Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences](https://longbridge.com/en/news/300681567.md)
- [Lakewood-Amedex reports positive MIC data for Nu-3 against infected diabetic foot ulcer isolates](https://longbridge.com/en/news/300302169.md)
- [Time to Nibble on MCD Stock After it Enters Oversold Territory?](https://longbridge.com/en/news/300812314.md)
- [Cathie Wood Is Buying Rocket Lab Again: Why 3 ARK ETFs Are Betting on Neutron](https://longbridge.com/en/news/300816393.md)
- [ARK's Winton says each Starship launch could add $700 million a year](https://longbridge.com/en/news/300832406.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**